Alan Russell Biography and Net Worth

Insider of Edgewise Therapeutics

Alan Russell, Ph.D., serves as our Co-Founder, Chief Scientific Officer and a member of our board of directors. Previously, Dr. Russell served at GlaxoSmithKline as VP and Head of the Muscle Metabolism Discovery Performance Unit, leading a broad discovery and development effort focused on patients for whom muscle function is compromised. Prior to this, he worked at Cytokinetics Inc. and is the co-inventor of Tirasemtiv and Reldesemtiv, direct muscle sensitizers in clinical trials for Amyotrophic Lateral Sclerosis (ALS). Dr. Russell received a B.Pharm. in Pharmacy and Pharmacology and Ph.D. in Cell Biology and Gene Therapy from the University of Bath in the UK and Postdoctoral training at the Stanford University School of Medicine.

What is Alan J. Russell's net worth?: The estimated net worth of Alan J. Russell is at least $345,862.01 as of February 6th, 2025. Dr. Russell owns 14,863 shares of Edgewise Therapeutics stock worth more than $345,862 as of March 29th. This net worth approximation does not reflect any other assets that Dr. Russell may own. Additionally, Dr. Russell receives an annual salary of $657,520.00 as Insider at Edgewise Therapeutics. Learn More about Alan J. Russell's net worth.
How old is Alan J. Russell?: Dr. Russell is currently 54 years old. There are 8 older executives and no younger executives at Edgewise Therapeutics. The oldest executive at Edgewise Therapeutics is Dr. Joanne M. Donovan M.D., Ph.D., Chief Medical Officer, who is 67 years old. Learn More on Alan J. Russell's age.
What is Alan J. Russell's salary?: As the Insider of Edgewise Therapeutics, Inc., Dr. Russell earns $657,520.00 per year. There are 2 executives that earn more than Dr. Russell. The highest earning executive at Edgewise Therapeutics is Dr. Kevin Koch Ph.D., President, CEO & Director, who commands a salary of $905,520.00 per year. Learn More on Alan J. Russell's salary.
How do I contact Alan J. Russell?: The corporate mailing address for Dr. Russell and other Edgewise Therapeutics executives is 3415 COLORADO AVE., BOULDER CO, 80303. Edgewise Therapeutics can also be reached via phone at 720-262-7002 and via email at ir@edgewisetx.com. Learn More on Alan J. Russell's contact information.
Has Alan J. Russell been buying or selling shares of Edgewise Therapeutics?: During the past quarter, Alan J. Russell has sold $36,156.00 in Edgewise Therapeutics stock. Most recently, Alan J. Russell sold 1,200 shares of the business's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $30.13, for a transaction totalling $36,156.00. Following the completion of the sale, the insider now directly owns 14,863 shares of the company's stock, valued at $447,822.19. Learn More on Alan J. Russell's trading history.
Who are Edgewise Therapeutics' active insiders?: Edgewise Therapeutics' insider roster includes R. Michael Carruthers (CFO), Behrad Derakhshan (Chief Business Officer), Joanne Donovan (CMO), Jonathan Fox (Director), Kevin Koch (President, CEO and Director), John Moore (General Counsel), Jonathan Root (Director), Alan Russell (Insider), and Peter Thompson (Chairman and Co-Founder). Learn More on Edgewise Therapeutics' active insiders.
Are insiders buying or selling shares of Edgewise Therapeutics?: During the last twelve months, insiders at the sold shares 15 times. They sold a total of 455,386 shares worth more than $12,738,116.72. The most recent insider tranaction occured on February, 6th when insider Alan J Russell sold 1,200 shares worth more than $36,156.00. Insiders at Edgewise Therapeutics own 24.1% of the company. Learn More about insider trades at Edgewise Therapeutics.
Information on this page was last updated on 2/6/2025.

Alan J. Russell Insider Trading History at Edgewise Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/6/2025	Sell	1,200	$30.13	$36,156.00	14,863
12/30/2024	Sell	100,000	$27.37	$2,737,000.00	14,863
9/20/2024	Sell	75,000	$28.27	$2,120,250.00	12,719
12/26/2023	Sell	172,585	$9.33	$1,610,218.05	3,606
11/8/2021	Sell	9,017	$20.16	$181,782.72
11/5/2021	Sell	13,042	$19.62	$255,884.04
11/3/2021	Sell	26,184	$18.18	$476,025.12
11/1/2021	Sell	469	$18.02	$8,451.38
10/14/2021	Sell	5,749	$18.18	$104,516.82
10/11/2021	Sell	1,270	$18.02	$22,885.40
10/8/2021	Sell	5,902	$18.15	$107,121.30
10/6/2021	Sell	2,108	$18.03	$38,007.24
10/4/2021	Sell	100	$18.00	$1,800.00
10/1/2021	Sell	274	$18.00	$4,932.00
9/29/2021	Sell	11,844	$16.86	$199,689.84
9/27/2021	Sell	11,611	$17.98	$208,765.78
9/23/2021	Sell	26,835	$18.54	$497,520.90

Alan J. Russell Buying and Selling Activity at Edgewise Therapeutics

Edgewise Therapeutics Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Today's Range

Now: $23.27

$22.62

$23.48

50 Day Range

MA: $26.27

$22.26

$30.03

2 Week Range

Now: $23.27

$14.90

$38.12

Volume

701,469 shs

Average Volume

964,004 shs

Market Capitalization

$2.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22

Alan Russell Biography and Net Worth

What is Alan J. Russell's net worth?

How old is Alan J. Russell?

What is Alan J. Russell's salary?

How do I contact Alan J. Russell?

Has Alan J. Russell been buying or selling shares of Edgewise Therapeutics?

Who are Edgewise Therapeutics' active insiders?

Are insiders buying or selling shares of Edgewise Therapeutics?